Low-Intensity Shockwave Therapy Improves Hemodynamic Parameters in Patients with Vasculagenic ED: A Triplex Ultrasonography-Based Sham-Controlled Trail

Dimitrios Kalyvianakis, MD, FECSM, Dimitrios Hatzichristou, MD, PhD, FECSM Center for Sexual and Reproductive Health, Aristotle University of Thessaloniki Greece, Thessaloniki, Greece

Abstract

Background: Although several reports have documented the subjective improvement of erectile function after low-intensity extracorporeal shockwave therapy (LI-ESWT) in patients with vasculogenic erectile dysfunction (ED), objective assessment data of penile hemodynamics are lacking.

Aim: To assess penile hemodynamics before and 3 months after LI-ESWT in a group of patients with documented vasculogenic ED.

Methods: This was a double-blinded, randomized, sham-controlled trial. Forty-six patients with ED were randomized; 30 underwent LI-ESWT and 16 had a sham procedure in double-blinded fashion. All patients underwent penile triplex ultrasonography by the same investigator immediately before and 3 months after treatment. Patient demographics, International Index of Erectile Function erectile function domain (IIEF-ED) score, and minimal clinically important difference were assessed at baseline and 1, 3, 6, 9, and 12 months after treatment.

Outcomes: Changes in peak systolic velocity and resistance index as measured by triplex ultrasonography at baseline and 3 months after treatment were the main outcomes of the study. Secondary outcomes were changes in the IIEF-EF score from baseline to 1, 3, 6, 9, and 12 months after treatment and the percentage of patients reaching a minimal clinically important difference during the same period for the two groups.

Results: IIEF-EF minimal clinically important differences for the active vs sham group were observed for 56.7% vs 12.5% (P = .005) at 1 month, 56.7% vs 12.5% (P = .003) at 3 months, 63.3% vs 18.8% (P = .006) at 6 months, 66.7% vs 31.3% (P = .022) at 9 months, and 75% vs 25% (P = .008) at 12 months. Mean peak systolic velocity increased by 4.5 and 0.6 cm/s in the LI-ESWT and sham groups, respectively (P < .001).

Clinical Implications: Such results offer objective and subjective documentation of the value of this novel treatment modality for men with vasculogenic ED.

Strengths and Limitations: Strengths include the prospective, randomized, sham-controlled type of study and the assessment of penile hemodynamics. Limitations include the small sample and strict inclusion criteria that do not reflect everyday clinical practice.

Conclusion: The present study confirms the beneficial effect of LI-ESWT on penile hemodynamics and the beneficial effect of this treatment up to 12 months.

Low Intensity Extracorporeal Shockwave Therapy (Li-ESWT) Improves Erectile Function in a Model of Type II Diabetes Independently of NO/cGMP Pathway

Rana Assaly-Kaddoum, Francois Giuliano, Miguel Laurin, Diane Gomy, Micheline Kergoat, Jacques Bernabe, Yoram Vardi, Laurent Alexandre, Delphine Behr-Roussel

Purpose:

Erectile Dysfunction (ED) is highly prevalent in type II diabetes mellitus (T2DM). Li-ESWT improves erectile function in patients with ED from vasculogenic origin including diabetes, although its mode of action remains unknown.

Penile low-intensity shockwave treatment is able to shift PDE5i non-responders to responders: A double-blind sham-controlled study

Kitrey ND, Gruenwald I, Appel B, Shechter A, Massarwa O, Vardi Y,

Purpose:

Sham-controlled evaluation of penile low-intensity shockwave treatment (LIST) effect on patients unable to have sexual intercourse with phosphodiesterase 5 inhibitors.

Impact of aging and comorbidity on the efficacy of low-intensity shock wave therapy for erectile dysfunc

Hisasue SI, China T, Horiuchi A, Kimura M, Saito K, Isotani S, Ide H, Muto S2, Yamaguchi R2, Horie S.

Objectives:

To evaluate the efficacy of low-intensity shock wave therapy and to identify the predictive factors of its efficacy in Japanese patients with erectile dysfunction.

The Safety and Efficacy of Li-ESWT in 604 patients for Erectile Dysfunction: Summary of Current and Evolving Evidence

Robert A. Feldman, Bela S. Denes, Boaz Appel, Satya S. Vasan, Tamar Shultz and Arthur L. Burnett

Objectives:

Low intensity shock wave therapy (Li-ESWT) is currently approved in over 20 countries and available at over 200 clinics worldwide. A US multicenter study has been completed and the data are currently under FDA review. Herein we provide an overview of the clinical experience to date on the safety and efficacy of Li-ESWT for the treatment of erectile dysfunction. Studies were conducted in men with ED considered responders and in men considered poor responders to PDE5i. We report pooled data from 5 randomized, placebo-controlled studies (USA, Israel, Greece and India) and 3 single-arm open label studies (Israel, Japan). Li-ESWT for ED has been recently included in the European Association of Urology guideline 2013 for male sexual dysfunction.

New Therapeutics for ED - Prof. Peter Lim, Singapore

UroFair 2015

Prof. Peter Lim, Singapore, in a lecture in which he presented his latest results using ED1000, during UroFair 2015.

Low Intensity Extracorporeal Shockwave Therapy for Erectile Dysfunction: a Study in an Indian Population

Srini Satya Vasan, Reddy Kumar Rahul, Shultz Tamar, Denes Bela

Erectile dysfunction (ED) has been shown to be associated with a number of physical conditions and affects not only physical but also psychosocial health. Currently oral, on-demand phosphodiesterase type 5 inhibitors (PDE5i) are preferred first line treatment. Though effective, these drugs have limitations and are associated with significant non-compliance, side effects and do not reverse the underlying pathology. Non-invasive low intensity shockwave therapy (LISWT) has been shown to significantly improve erectile function in men previously PDE5i dependent. The study describe the experience and results with this therapy in an Indian population of men with ED. It assessed the efficacy of low intensity extracorporeal shockwave therapy (LI-ESWT) on Indian men with organic ED who had previously responded to PDE5i.

EDSWT is the gold standard for the Treatment of ED

Low Intensity Shock Wave Therapy (EDSWT) was officially accepted by the European Association of Urology (EAU) as the gold standard for treatments of Erectile Dysfunction in the EAU 2013 guidelines on Male Sexual Dysfunction. This was based on clinical trials using the Medispec’s ED1000.

Penile Low-Intensity Shock Wave Therapy: A Promising Novel Modality for Erectile Dysfunction

Yasmin Abu-Ghanem,* Noam D. Kitrey,* Ilan Gruenwald, Boaz Appel, and Yoram Vardi

Penile extracorporeal low-intensity shock wave therapy (LIST) to the penis has recently emerged as a novel and promising modality in the treatment of erectile dysfunction (ED). LIST has angiogenic properties and stimulates neovascularization.

The Low-Intensity Shock Wave Therapy for Erectile Dysfunction

Shin-ichi Hisasue, M.D. Ph.D.

I’Phosphodiesterase type 5 inhibitors (PDE5i) revolutionized the treatment of erectile dysfunction (ED). However, even in vasculogenic ED patients, one fifth of them showed poor response to PDE5i. Low-intensity shock wave therapy (LI-ESWT) is a novel and promising modality for the patients with mild to moderate erectile dysfunction (ED).

Shockwave Treatment of Erectile Dysfunction

Ilan Gruenwald, Boaz Appel, Noam D. Kitrey and Yoram Vardi

Low-intensity extracorporeal shock wave therapy (LI-ESWT) is a novel modality that has recently been developed for treating erectile dysfunction (ED). Unlike other current treatment options for ED, all of which are palliative in nature, LI-ESWT is unique in that it aims to restore the erectile mechanism in order to enable natural or spontaneous erections.

Does Low Intensity Extracorporeal Shock Wave Therapy Have a Physiological Effect on Erectile Function? Short-Term Results of a Randomized, Double-Blind, Sham Controlled Study

Yoram Vardi, Boaz Appel, Amichai Kilchevsky, Ilan Gruenwald

Purpose:

We investigated the clinical and physiological effect of low intensity extracorporeal shock wave therapy on men with organic erectile dysfunction who are phosphodiesterase type 5 inhibitor responders.